# Cholinergic reflex control of inflammation: mechanistic and translational advances in transcutaneous auricular vagus nerve stimulation across rheumatic, metabolic, and postoperative disorders

**Authors:** Rui Han, Zongbo Peng, Ming Zhuo, Yuanyuan Song, Yuhao Liu, Xiaowen Zhang, Zihao Deng, Lingyi Xia, Mao-Lin Zhong

PMC · DOI: 10.3389/fimmu.2025.1702185 · Frontiers in Immunology · 2026-01-21

## TL;DR

This review explores how stimulating the vagus nerve through the ear can reduce inflammation in various diseases, including arthritis and post-surgery conditions.

## Contribution

The paper provides a comprehensive synthesis of the mechanisms and applications of taVNS in treating inflammatory disorders.

## Key findings

- taVNS shows anti-inflammatory efficacy in rheumatoid arthritis and systemic lupus erythematosus.
- Stimulation parameters significantly influence the therapeutic outcomes of taVNS.
- taVNS is being investigated for postoperative inflammation and metabolic syndrome.

## Abstract

Transcutaneous auricular vagus nerve stimulation (taVNS) has recently emerged as a focal noninvasive neuromodulatory approach in anti-inflammatory therapeutics. The vagus nerve functions as a critical neuroimmune interface, tonically suppressing proinflammatory cytokine release via the cholinergic anti-inflammatory pathway (CAP). This mechanism provides substantial therapeutic potential across a spectrum of inflammatory disorders, including postoperative systemic inflammation. Clinical trials have demonstrated the anti-inflammatory efficacy of taVNS, supporting its expanded use in rheumatoid arthritis, systemic lupus erythematosus, gout, inflammatory bowel disease (IBD), and other immune-mediated disorders. Investigations into postoperative inflammation and metabolic syndrome are now emerging. In this review, we synthesize the anatomical substrate, mechanistic framework, and disease-specific applications of taVNS, with a particular emphasis on how stimulation parameters influence therapeutic outcomes. Finally, we outline current challenges and propose future directions to advance research and clinical translation.

## Linked entities

- **Diseases:** rheumatoid arthritis (MONDO:0008383), systemic lupus erythematosus (MONDO:0007915), gout (MONDO:0005393), inflammatory bowel disease (MONDO:0005265), metabolic syndrome (MONDO:0000816)

## Full-text entities

- **Diseases:** gout (MESH:D006073), metabolic syndrome (MESH:D024821), immune-mediated disorders (MESH:C567355), rheumatic, metabolic, and postoperative disorders (MESH:D012216), inflammation (MESH:D007249), systemic (MESH:D015619), rheumatoid arthritis (MESH:D001172), IBD (MESH:D015212), systemic lupus erythematosus (MESH:D008180)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12869026/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12869026/full.md

## References

89 references — full list in the complete paper: https://tomesphere.com/paper/PMC12869026/full.md

---
Source: https://tomesphere.com/paper/PMC12869026